The Century of History Shaping the Debate Over GLP-1s

The Century of History Shaping the Debate Over GLP-1s

The debate over whether insurers should pay for GLP-1 drugs like Ozempic and Wegovy has revived a familiar American argument about why people get sick. Some commentators have insisted that the powerful weight-loss drugs are “shortcuts” for people unwilling to exercise greater self-control, a concern echoed in coverage noting that experts worry too many patients may be trying GLP-1s as a shortcut instead of improving their diet and exercise. Othe…